<?xml version="1.0" encoding="UTF-8"?>

<?xml-stylesheet type="text/xsl" href="/static/oaitohtml.xsl"?>

<!--
<?xml-stylesheet type="text/xsl" href="/oaitohtml.xsl"?>
-->

<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <responseDate>2026-10-10T10:13:01Z</responseDate>
    <request verb="GetRecord" metadataPrefix="oai_dc" identifier="10.57760/sciencedb.36447" >https://www.scidb.cn/oai</request>
<GetRecord>
    <record>
    <header >
    <identifier>10.57760/sciencedb.36447</identifier>
    <datestamp>2026-05-14T10:11:29Z</datestamp>
</header>
    <metadata>
        
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:date>2026-05-14</dc:date>
  <dc:title>Clinical Biochemical Test Data for Early-Stage Colon Adenocarcinoma (COAD) Patients</dc:title>
  <dc:identifier>doi:10.57760/sciencedb.36447</dc:identifier>
  <dc:language>en</dc:language>
  <dc:description>This dataset was generated from a multicenter cohort study conducted between May 2025 and December 2025, including 305 participants, comprising 205 newly diagnosed, treatment-naive patients with early-stage colon adenocarcinoma and 100 healthy controls. All cancer cases were histopathologically confirmed. Peripheral blood samples were collected at the time of outpatient diagnosis prior to treatment initiation, while samples from healthy controls were obtained during routine health examinations, with colorectal disease excluded by colonoscopy.The dataset contains comprehensive clinical and laboratory data derived from these participants, including serum biochemical indicators, tumor markers, immune cell profiling, and genomic mutation information.Serum biochemical data were obtained using an automated clinical chemistry analyzer under standardized laboratory conditions. The dataset includes quantitative measurements of multiple proteins and enzymes related to lipid metabolism, liver function, oxidative stress, and inflammation (e.g., APOA1, APOB, APOE, ALB, TTR, CP, CYSC, NGAL, TF, GSR, ADA, and others). Tumor marker data include commonly used clinical indicators such as CEA, CA125, and CA199.Immune-related data were generated from flow cytometry analysis of peripheral blood samples. The dataset provides proportions of lymphocyte subsets, including T cells (CD3⁺, CD4⁺, CD8⁺), B cells, and NK cells, as well as expression levels of immune checkpoint molecules such as PD-1.Genomic data were obtained from formalin-fixed paraffin-embedded tumor tissues using targeted next-generation sequencing. The dataset includes mutation profiles of key cancer-related genes, such as TP53, APC, KRAS, BRAF, and PIK3CA.Each data file is organized in tabular format, where rows represent individual participants and columns represent specific variables. Column names correspond to clinical indicators, laboratory measurements, or genetic features. Continuous variables are recorded as numerical values with standard units, while categorical variables are coded numerically or textually as appropriate.This dataset provides valuable resources for investigating the diagnostic value of serum biomarkers, exploring immune characteristics, and analyzing molecular alterations in early-stage colon adenocarcinoma. It can be used for biomarker discovery, risk stratification, and integrative multi-omics analysis.</dc:description>
  <dc:subject>COAD; ML; Clinical Biochemical Testing </dc:subject>
  <dc:creator>Chengyuan Dong</dc:creator>
  <dc:rights>PUBLIC</dc:rights>
  <dc:rights>https://creativecommons.org/licenses/by-nc/4.0/</dc:rights>
  <dc:type>dataset</dc:type>
  <dc:publisher>Science Data Bank</dc:publisher>
</oai_dc:dc>

    </metadata>
</record>
</GetRecord>
</OAI-PMH>